HCAT Earnings

HCAT reported its FY2025Q4 earnings on 2026-02-26, showcasing a revenue of against an estimate of 73.61M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following HCAT's FY2025Q4 earnings announcement on 2026-02-26, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, HCAT's stock price tends to shift by an average of +9.43% in the 10 days leading up to earnings and -1.38% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate HCAT’s annual revenue to reach 73.94M, while the EPS is projected at 0.10. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.59% and EPS estimates Revise Downward by -1.14% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between HCAT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.59%, while EPS estimates moved Revise Downward by -1.14% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, HCAT's stock price typically moves by +9.43% in the 10 days before its earnings and -1.38% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.10 and revenue of 73.94M.

The earnings call presents mixed signals: the company reports revenue growth and exceeded EBITDA guidance, but faces macroeconomic and competitive pressures. The share repurchase program is positive, but the decline in gross margins and cash reserves, coupled with uncertain economic conditions, offset this. The Q&A indicates confidence in new client acquisition and tech margin improvement, but management's vague responses on Medicaid cuts raise concerns. Overall, the positive aspects are balanced by significant risks and uncertainties, leading to a neutral sentiment.